JP2005533051A5 - - Google Patents

Download PDF

Info

Publication number
JP2005533051A5
JP2005533051A5 JP2004511296A JP2004511296A JP2005533051A5 JP 2005533051 A5 JP2005533051 A5 JP 2005533051A5 JP 2004511296 A JP2004511296 A JP 2004511296A JP 2004511296 A JP2004511296 A JP 2004511296A JP 2005533051 A5 JP2005533051 A5 JP 2005533051A5
Authority
JP
Japan
Prior art keywords
disease
injury
peripheral
alopecia
metastases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004511296A
Other languages
English (en)
Japanese (ja)
Other versions
JP4441401B2 (ja
JP2005533051A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/FR2003/001686 external-priority patent/WO2003104226A1/fr
Publication of JP2005533051A publication Critical patent/JP2005533051A/ja
Publication of JP2005533051A5 publication Critical patent/JP2005533051A5/ja
Application granted granted Critical
Publication of JP4441401B2 publication Critical patent/JP4441401B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004511296A 2002-06-07 2003-06-05 ピペラジニルアシルピペリジン誘導体、それらの製造およびそれらの治療的用途 Expired - Fee Related JP4441401B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0207001 2002-06-07
PCT/FR2003/001686 WO2003104226A1 (fr) 2002-06-07 2003-06-05 Derives de piperazinylacylpiperidine, leur preparation et leur application en therapeutique

Publications (3)

Publication Number Publication Date
JP2005533051A JP2005533051A (ja) 2005-11-04
JP2005533051A5 true JP2005533051A5 (https=) 2006-05-11
JP4441401B2 JP4441401B2 (ja) 2010-03-31

Family

ID=29724874

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004511296A Expired - Fee Related JP4441401B2 (ja) 2002-06-07 2003-06-05 ピペラジニルアシルピペリジン誘導体、それらの製造およびそれらの治療的用途
JP2004511295A Expired - Fee Related JP4437075B2 (ja) 2002-06-07 2003-06-05 ピペラジニルアシルピペリジン誘導体、それらの製造方法およびそれらの治療的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004511295A Expired - Fee Related JP4437075B2 (ja) 2002-06-07 2003-06-05 ピペラジニルアシルピペリジン誘導体、それらの製造方法およびそれらの治療的用途

Country Status (29)

Country Link
US (2) US7468368B2 (https=)
EP (2) EP1513836B1 (https=)
JP (2) JP4441401B2 (https=)
KR (1) KR100970812B1 (https=)
CN (1) CN100448875C (https=)
AR (2) AR040246A1 (https=)
AT (2) ATE325122T1 (https=)
AU (2) AU2003255645A1 (https=)
BR (1) BR0311828A (https=)
CA (1) CA2487840C (https=)
CY (2) CY1107330T1 (https=)
DE (2) DE60305037T2 (https=)
DK (2) DK1513835T3 (https=)
EA (1) EA007501B1 (https=)
ES (2) ES2264001T3 (https=)
HR (1) HRP20041157B1 (https=)
IS (1) IS2302B (https=)
MA (1) MA27233A1 (https=)
ME (1) MEP11508A (https=)
MX (1) MXPA04012341A (https=)
NO (1) NO329669B1 (https=)
NZ (1) NZ537044A (https=)
PL (1) PL208711B1 (https=)
PT (2) PT1513835E (https=)
RS (2) RS52588B (https=)
TW (2) TWI283671B (https=)
UA (1) UA77526C2 (https=)
WO (2) WO2003104225A1 (https=)
ZA (1) ZA200409823B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
US7723362B2 (en) * 2004-01-08 2010-05-25 Syngenta Crop Protection, Inc. Pesticidal heterocyclic dihaloallyl compounds
KR20070036148A (ko) * 2004-07-16 2007-04-02 얀센 파마슈티카 엔.브이. 신경병성 질환의 치료에 적합한 피페리딘, 피페라진 혹은모르폴린의 이량체 화합물 또는 그들의 7-원 유사체
EP2289510A1 (en) * 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
EP1871420A4 (en) * 2005-04-15 2010-09-22 Univ North Carolina PROCESS FOR ENABLING CELL SURVIVAL VIA NEUROTROPHINE MIMETICS
EP2137179B1 (en) * 2007-03-15 2015-09-02 Merck Sharp & Dohme Corp. Pyridazinone derivatives useful as glucan synthase inhibitors
EP2162135A4 (en) * 2007-05-21 2012-02-22 Reviva Pharmaceuticals Inc COMPOSITIONS, SYNTHESIS AND METHOD FOR THE APPLICATION OF ATTAINED CHINOLINONE-BASED ANTIPSYCHOTICS
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
FR2932481B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
FR2932482B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
ES2712752T3 (es) 2009-11-12 2019-05-14 Pharmatrophix Inc Formas cristalinas de compuestos miméticos de neurotrofina y sus sales
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US9062015B2 (en) 2009-12-14 2015-06-23 Merck Patent Gmbh Inhibitors of sphingosine kinase
FR2953836B1 (fr) * 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
US12435078B2 (en) 2017-09-18 2025-10-07 Gfb (Abc), Llc Pyridazinones and methods of use thereof
CN112911935A (zh) 2018-09-18 2021-06-04 金翅雀生物公司 哒嗪酮及其使用方法
CA3136632A1 (en) 2019-04-11 2020-10-15 Goldfinch Bio, Inc. Spray-dried formulation of a pyridazinone trpc5 inhibitor
EP3858439A1 (en) * 2020-02-03 2021-08-04 Esteve Pharmaceuticals, S.A. Amide derivatives having multimodal activity against pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994455A (en) * 1987-10-26 1991-02-19 Pfizer Inc. Anti-anxiety agents
FR2747041B1 (fr) * 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US6468990B1 (en) * 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
FR2803593B1 (fr) 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant

Similar Documents

Publication Publication Date Title
JP2005533051A5 (https=)
JP2005534661A5 (https=)
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
IL180979A (en) Isoindulin compounds and their use
NO20043237L (no) Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
WO2004080423A3 (en) 7-amino- isoindolyl compounds amd their pharmaceutical uses
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
SI1511710T1 (sl) Spojine, sestavki in postopki za zdravljenje amiloidnih bolezni in sinukleinopatij, kot je Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsova bolezen
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
NO20053678D0 (no) Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
TW200736196A (en) 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
CY2015025I2 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
SI1660057T1 (sl) Kombinirana terapija za zdravljenje okularnih neovaskularnih nepravilnosti
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
LTC1562603I2 (lt) Nauji vaistai, skirti lėtinių obstrukcinių plaučių ligų gydymui
TW200745135A (en) Therapeutic agents
ITMI20031311A0 (it) Formulazioni per il trattamento di disturbi artrosici
PL377715A1 (pl) Antagoniści CCR1 do leczenia między innymi demielizacyjnej choroby zapalnej
UA88634C2 (en) Quaternized quinuclidine esters
NO20055098D0 (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
WO2008125902A3 (en) Peripheral and neural inflammatory crosstalk
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
AU2003274885A1 (en) Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders
WO2005020904A3 (en) Oral neurotherapeutic cefazolin compositions